DE69526425D1 - Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen - Google Patents

Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen

Info

Publication number
DE69526425D1
DE69526425D1 DE69526425T DE69526425T DE69526425D1 DE 69526425 D1 DE69526425 D1 DE 69526425D1 DE 69526425 T DE69526425 T DE 69526425T DE 69526425 T DE69526425 T DE 69526425T DE 69526425 D1 DE69526425 D1 DE 69526425D1
Authority
DE
Germany
Prior art keywords
mometasone
furoat
lung diseases
treat air
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69526425T
Other languages
English (en)
Other versions
DE69526425T2 (de
Inventor
A Sequeira
M Cuss
B Nolop
A Chaudry
Nagamani Nagabhushan
E Patrick
Mitchell Cayen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22692858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69526425(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69526425D1 publication Critical patent/DE69526425D1/de
Application granted granted Critical
Publication of DE69526425T2 publication Critical patent/DE69526425T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69526425T 1994-01-27 1995-01-26 Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen Expired - Lifetime DE69526425T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18837294A 1994-01-27 1994-01-27
PCT/US1995/000550 WO1995020393A1 (en) 1994-01-27 1995-01-26 Use of mometasone furoate for treating airway passage and lung diseases

Publications (2)

Publication Number Publication Date
DE69526425D1 true DE69526425D1 (de) 2002-05-23
DE69526425T2 DE69526425T2 (de) 2002-12-05

Family

ID=22692858

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526425T Expired - Lifetime DE69526425T2 (de) 1994-01-27 1995-01-26 Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen

Country Status (29)

Country Link
EP (6) EP1174139B1 (de)
JP (6) JP3480736B2 (de)
KR (1) KR100234864B1 (de)
CN (4) CN100358528C (de)
AT (5) ATE531364T1 (de)
AU (1) AU691880B2 (de)
CA (1) CA2182086C (de)
CO (1) CO4340692A1 (de)
CY (2) CY2616B2 (de)
CZ (1) CZ219196A3 (de)
DE (1) DE69526425T2 (de)
DK (3) DK2156840T3 (de)
ES (3) ES2368827T3 (de)
FI (2) FI122395B (de)
HK (5) HK1040912A1 (de)
HU (1) HU227837B1 (de)
IL (1) IL112459A (de)
MX (1) MX9602246A (de)
MY (1) MY114665A (de)
NO (2) NO314535B1 (de)
NZ (1) NZ279979A (de)
PE (1) PE44995A1 (de)
PL (1) PL315575A1 (de)
PT (3) PT740550E (de)
SG (1) SG47387A1 (de)
SK (1) SK283338B6 (de)
TW (1) TW329387B (de)
WO (1) WO1995020393A1 (de)
ZA (1) ZA95637B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5962445A (en) * 1996-05-09 1999-10-05 Amrad Operations Pty Ltd. Treatment of asthma and airway diseases
PT927037E (pt) * 1996-08-29 2001-10-31 Schering Corp Formulacoes em aerossol de furoato de mometasona sem clorofluorocarbonetos
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
DK1393721T3 (da) * 1997-03-20 2009-03-30 Schering Corp Doseringsform af pulveragglomerater
CA2305256C (en) * 1997-10-09 2005-05-17 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
WO2001026658A2 (en) * 1999-10-08 2001-04-19 Schering Corporation Topical nasal treatment using desloratadine
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
JP3691487B2 (ja) * 2000-12-22 2005-09-07 久光メディカル株式会社 炎症性気道疾患の予防・治療剤
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1667687A1 (de) * 2003-09-26 2006-06-14 Schering Corporation Behandlung von lungenerkrankung
WO2005037245A2 (en) * 2003-10-21 2005-04-28 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
CA2543482A1 (en) * 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
PL1711164T3 (pl) * 2004-01-21 2010-09-30 Merck Sharp & Dohme Sposób leczenia ostrego zapalenia zatok przynosowych
WO2006043655A1 (ja) * 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. 吸入用医薬組成物
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
SI3354276T1 (sl) 2007-11-13 2020-09-30 Meritage Pharma, Inc. Sestavki za zdravljenje gastrointestinalnega vnetja
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
WO2010021636A1 (en) * 2008-08-20 2010-02-25 The Regents Of The University Of California Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
EP2349206A2 (de) * 2008-10-10 2011-08-03 Schering Corporation Kortikosteroidzusammensetzungen und behandlungsverfahren
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
EP2922553A1 (de) 2013-10-04 2015-09-30 Glenmark Pharmaceuticals Limited Behandlung von allergischer rhinitis unter verwendung einer kombination von mometason und olopatadin
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN107260665B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种吸入用糠酸莫米松混悬液组合物
AU2019224850A1 (en) 2018-02-23 2020-08-13 Glenmark Specialty S.A. Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
CN113933415B (zh) * 2021-09-30 2023-03-24 北京阳光德美医药科技有限公司 一种hplc-ms/ms测定人血浆中糠酸酯浓度的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4972830A (en) 1985-07-31 1990-11-27 Vortran Medical Technology, Inc. Inhalation device and method
US4873335A (en) 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
US4910192A (en) * 1987-12-04 1990-03-20 Sri International Topically active steroidal anti-inflammatory agents
EP0705614B1 (de) * 1989-04-28 2002-09-25 Riker Laboratories, Inc. Inhalationsvorrichtung für Trockenpulver
AU654813B2 (en) * 1990-03-23 1994-11-24 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
PL165803B1 (pl) 1990-09-10 1995-02-28 Schering Corp Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL
ES2096665T3 (es) * 1990-10-16 1997-03-16 John Lezdey Tratamiento de la inflamacion.
DE69105212T2 (de) * 1990-10-18 1995-03-23 Minnesota Mining & Mfg Aerosolzubereitung, die beclometason 17,21-dipropionat enthält.
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
DE69231991T2 (de) * 1991-06-10 2002-04-04 Schering Corp Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
PT656207E (pt) * 1991-06-10 2001-11-30 Schering Corp Formulacoes de aerossois sem clorofluorocarbonetos
DE69210607T2 (de) * 1991-06-26 1996-09-26 Schering Corp Inhalator für Medikamente in Pulverform
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
ATE128350T1 (de) * 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
AU663905B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
DK0630230T3 (da) * 1992-03-10 1997-06-02 Fisons Plc Farmaceutiske inhaleringspræparater
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Also Published As

Publication number Publication date
IL112459A (en) 1999-04-11
FI122395B (fi) 2011-12-30
EP2156840A3 (de) 2010-05-19
JPH11286447A (ja) 1999-10-19
CN100441192C (zh) 2008-12-10
JP2008285497A (ja) 2008-11-27
ATE519489T1 (de) 2011-08-15
PE44995A1 (es) 1995-12-18
EP1201242A2 (de) 2002-05-02
DK0740550T3 (da) 2002-06-24
SG47387A1 (en) 1998-04-17
EP1201242B1 (de) 2011-11-02
DK2156840T3 (da) 2011-11-21
CN1139384A (zh) 1997-01-01
JP2008031184A (ja) 2008-02-14
HK1040918A1 (zh) 2002-06-28
NO963132L (no) 1996-09-26
ZA95637B (en) 1995-07-26
EP2156840A2 (de) 2010-02-24
TW329387B (en) 1998-04-11
HK1135331A1 (en) 2010-06-04
CN1531967A (zh) 2004-09-29
DK1174138T3 (da) 2011-11-21
FI962828A0 (fi) 1996-07-12
ES2173947T3 (es) 2002-11-01
HUT74884A (en) 1997-02-28
CZ219196A3 (en) 1996-12-11
ES2368827T3 (es) 2011-11-22
JP5247265B2 (ja) 2013-07-24
HK1040911A1 (en) 2002-06-28
CN101156860A (zh) 2008-04-09
PT2156840E (pt) 2011-10-18
HK1041829A1 (zh) 2002-07-26
EP1201242A3 (de) 2003-12-03
EP1174138B1 (de) 2011-08-03
CY2616B2 (en) 2012-05-23
ES2369516T3 (es) 2011-12-01
SK82296A3 (en) 1997-03-05
CY2617B2 (en) 2012-05-23
MY114665A (en) 2002-12-31
SK283338B6 (sk) 2003-06-03
EP1174139B1 (de) 2011-09-21
EP1174139A3 (de) 2002-01-30
AU691880B2 (en) 1998-05-28
CA2182086A1 (en) 1995-08-03
NO20025002L (no) 1996-09-26
PT740550E (pt) 2002-08-30
HU227837B1 (en) 2012-05-02
NZ279979A (en) 2001-03-30
NO328698B1 (no) 2010-04-26
AU1727195A (en) 1995-08-15
NO314535B1 (no) 2003-04-07
EP1174138A3 (de) 2002-01-30
CN100358528C (zh) 2008-01-02
IL112459A0 (en) 1995-03-30
KR100234864B1 (ko) 1999-12-15
EP1174138A2 (de) 2002-01-23
ATE531364T1 (de) 2011-11-15
PT1174138E (pt) 2011-10-03
EP0740550B1 (de) 2002-04-17
NO20025002D0 (no) 2002-10-17
HK1040911B (zh) 2011-11-18
HK1040912A1 (zh) 2002-06-28
NO963132D0 (no) 1996-07-26
PL315575A1 (en) 1996-11-12
FI123580B (fi) 2013-07-31
ATE216243T1 (de) 2002-05-15
JP3480736B2 (ja) 2003-12-22
HU9602043D0 (en) 1996-09-30
FI20115742A (fi) 2011-07-08
JP2012036222A (ja) 2012-02-23
EP1192946A1 (de) 2002-04-03
FI962828A (fi) 1996-07-12
CO4340692A1 (es) 1996-07-30
EP0740550A1 (de) 1996-11-06
ATE518520T1 (de) 2011-08-15
JPH09501700A (ja) 1997-02-18
CN101164542A (zh) 2008-04-23
DE69526425T2 (de) 2002-12-05
EP1174139A2 (de) 2002-01-23
EP2156840B1 (de) 2011-08-10
WO1995020393A1 (en) 1995-08-03
MX9602246A (es) 1997-07-31
JP2003313128A (ja) 2003-11-06
ATE525075T1 (de) 2011-10-15
CA2182086C (en) 2000-04-11

Similar Documents

Publication Publication Date Title
DE69526425D1 (de) Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen
CY1109030T1 (el) Συνθεση για εισπνοη

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings